These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21352805)

  • 41. RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways.
    Nakao A; Fukushima H; Kajiya H; Ozeki S; Okabe K
    Biochem Biophys Res Commun; 2007 Jun; 357(4):945-50. PubMed ID: 17467668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual modulation of osteoclast differentiation by lipopolysaccharide.
    Zou W; Bar-Shavit Z
    J Bone Miner Res; 2002 Jul; 17(7):1211-8. PubMed ID: 12096834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IL-1 plays an important role in the bone metabolism under physiological conditions.
    Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
    Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF; Lie A; Ransjö M
    J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
    J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
    Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
    Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The mechanism of osteoclast differentiation induced by IL-1.
    Kim JH; Jin HM; Kim K; Song I; Youn BU; Matsuo K; Kim N
    J Immunol; 2009 Aug; 183(3):1862-70. PubMed ID: 19587010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Water extract of the fruits of Alpinia oxyphylla inhibits osteoclast differentiation and bone loss.
    Ha H; Shim KS; Kim T; Lee CJ; Park JH; Kim HS; Ma JY
    BMC Complement Altern Med; 2014 Sep; 14():352. PubMed ID: 25249312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
    Park B
    Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
    Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ
    J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mollugin from Rubea cordifolia suppresses receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorbing activity in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
    Baek JM; Kim JY; Jung Y; Moon SH; Choi MK; Kim SH; Lee MS; Kim I; Oh J
    Phytomedicine; 2015 Jan; 22(1):27-35. PubMed ID: 25636867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanism of inhibitory action of eldecalcitol, an active vitamin D analog, on bone resorption in vivo.
    Takahashi N
    J Steroid Biochem Mol Biol; 2013 Jul; 136():171-4. PubMed ID: 23220095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways.
    Li H; Zhai Z; Liu G; Tang T; Lin Z; Zheng M; Qin A; Dai K
    Biochem Biophys Res Commun; 2013 Jan; 430(3):951-6. PubMed ID: 23261473
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RANKL synthesized by both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced by oral cancer.
    Sato K; Lee JW; Sakamoto K; Iimura T; Kayamori K; Yasuda H; Shindoh M; Ito M; Omura K; Yamaguchi A
    Am J Pathol; 2013 May; 182(5):1890-9. PubMed ID: 23499553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beta-Cryptoxanthin Inhibits Lipopolysaccharide-Induced Osteoclast Differentiation and Bone Resorption via the Suppression of Inhibitor of NF-κB Kinase Activity.
    Hirata N; Ichimaru R; Tominari T; Matsumoto C; Watanabe K; Taniguchi K; Hirata M; Ma S; Suzuki K; Grundler FMW; Miyaura C; Inada M
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30744180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of a proton pump inhibitor on bone metabolism in ovariectomized rats.
    Joo MK; Park JJ; Lee BJ; Kim JH; Yeon JE; Kim JS; Byun KS; Bak YT
    Mol Med Rep; 2013 Apr; 7(4):1267-72. PubMed ID: 23426758
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption.
    Chen CL; Liu FL; Lee CC; Chen TC; Ahmed Ali AA; Sytwu HK; Chang DM; Huang HS
    J Med Chem; 2014 Oct; 57(19):8072-85. PubMed ID: 25200306
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mevalonate-suppressive dietary isoprenoids for bone health.
    Mo H; Yeganehjoo H; Shah A; Mo WK; Soelaiman IN; Shen CL
    J Nutr Biochem; 2012 Dec; 23(12):1543-51. PubMed ID: 22981371
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lectin-like oxidized low-density lipoprotein receptor-1 abrogation causes resistance to inflammatory bone destruction in mice, despite promoting osteoclastogenesis in the steady state.
    Nakayachi M; Ito J; Hayashida C; Ohyama Y; Kakino A; Okayasu M; Sato T; Ogasawara T; Kaneda T; Suda N; Sawamura T; Hakeda Y
    Bone; 2015 Jun; 75():170-82. PubMed ID: 25744064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Natural products for treatment of bone erosive diseases: The effects and mechanisms on inhibiting osteoclastogenesis and bone resorption.
    An J; Hao D; Zhang Q; Chen B; Zhang R; Wang Y; Yang H
    Int Immunopharmacol; 2016 Jul; 36():118-131. PubMed ID: 27131574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.